163 related articles for article (PubMed ID: 21209911)
1. 1, 9-Pyrazoloanthrones downregulate HIF-1α and sensitize cancer cells to cetuximab-mediated anti-EGFR therapy.
Lu Y; Li X; Lu H; Fan Z
PLoS One; 2010 Dec; 5(12):e15823. PubMed ID: 21209911
[TBL] [Abstract][Full Text] [Related]
2. Responses of cancer cells with wild-type or tyrosine kinase domain-mutated epidermal growth factor receptor (EGFR) to EGFR-targeted therapy are linked to downregulation of hypoxia-inducible factor-1alpha.
Lu Y; Liang K; Li X; Fan Z
Mol Cancer; 2007 Oct; 6():63. PubMed ID: 17931419
[TBL] [Abstract][Full Text] [Related]
3. Requirement of hypoxia-inducible factor-1alpha down-regulation in mediating the antitumor activity of the anti-epidermal growth factor receptor monoclonal antibody cetuximab.
Li X; Lu Y; Liang K; Pan T; Mendelsohn J; Fan Z
Mol Cancer Ther; 2008 May; 7(5):1207-17. PubMed ID: 18483308
[TBL] [Abstract][Full Text] [Related]
4. The antiepidermal growth factor receptor monoclonal antibody cetuximab/C225 reduces hypoxia-inducible factor-1 alpha, leading to transcriptional inhibition of vascular endothelial growth factor expression.
Luwor RB; Lu Y; Li X; Mendelsohn J; Fan Z
Oncogene; 2005 Jun; 24(27):4433-41. PubMed ID: 15806152
[TBL] [Abstract][Full Text] [Related]
5. The anti-EGFR antibody cetuximab sensitizes human head and neck squamous cell carcinoma cells to radiation in part through inhibiting radiation-induced upregulation of HIF-1α.
Lu H; Liang K; Lu Y; Fan Z
Cancer Lett; 2012 Sep; 322(1):78-85. PubMed ID: 22348829
[TBL] [Abstract][Full Text] [Related]
6. Differential impact of EGFR-targeted therapies on hypoxia responses: implications for treatment sensitivity in triple-negative metastatic breast cancer.
El Guerrab A; Zegrour R; Nemlin CC; Vigier F; Cayre A; Penault-Llorca F; Rossignol F; Bignon YJ
PLoS One; 2011; 6(9):e25080. PubMed ID: 21966417
[TBL] [Abstract][Full Text] [Related]
7. The epidermal growth factor receptor antibody cetuximab induces autophagy in cancer cells by downregulating HIF-1alpha and Bcl-2 and activating the beclin 1/hVps34 complex.
Li X; Fan Z
Cancer Res; 2010 Jul; 70(14):5942-52. PubMed ID: 20634405
[TBL] [Abstract][Full Text] [Related]
8. Cetuximab reverses the Warburg effect by inhibiting HIF-1-regulated LDH-A.
Lu H; Li X; Luo Z; Liu J; Fan Z
Mol Cancer Ther; 2013 Oct; 12(10):2187-99. PubMed ID: 23920275
[TBL] [Abstract][Full Text] [Related]
9. Functional cooperation between HIF-1α and c-Jun in mediating primary and acquired resistance to gefitinib in NSCLC cells with activating mutation of EGFR.
Meng S; Wang G; Lu Y; Fan Z
Lung Cancer; 2018 Jul; 121():82-90. PubMed ID: 29858032
[TBL] [Abstract][Full Text] [Related]
10. Cetuximab enhances the activities of irinotecan on gastric cancer cell lines through downregulating the EGFR pathway upregulated by irinotecan.
Liu X; Guo WJ; Zhang XW; Cai X; Tian S; Li J
Cancer Chemother Pharmacol; 2011 Oct; 68(4):871-8. PubMed ID: 21286718
[TBL] [Abstract][Full Text] [Related]
11. In vitro study of normoxic epidermal growth factor receptor-induced hypoxia-inducible factor-1-alpha, vascular endothelial growth factor, and BNIP3 expression in head and neck squamous cell carcinoma cell lines: Implications for anti-epidermal growth factor receptor therapy.
Secades P; de Santa-María IS; Merlo A; Suarez C; Chiara MD
Head Neck; 2015 Aug; 37(8):1150-62. PubMed ID: 24798801
[TBL] [Abstract][Full Text] [Related]
12. Cross-talk between epidermal growth factor receptor and hypoxia-inducible factor-1alpha signal pathways increases resistance to apoptosis by up-regulating survivin gene expression.
Peng XH; Karna P; Cao Z; Jiang BH; Zhou M; Yang L
J Biol Chem; 2006 Sep; 281(36):25903-14. PubMed ID: 16847054
[TBL] [Abstract][Full Text] [Related]
13. Matuzumab and cetuximab activate the epidermal growth factor receptor but fail to trigger downstream signaling by Akt or Erk.
Yoshida T; Okamoto I; Okabe T; Iwasa T; Satoh T; Nishio K; Fukuoka M; Nakagawa K
Int J Cancer; 2008 Apr; 122(7):1530-8. PubMed ID: 18033688
[TBL] [Abstract][Full Text] [Related]
14. Wogonin inhibits tumor angiogenesis via degradation of HIF-1α protein.
Song X; Yao J; Wang F; Zhou M; Zhou Y; Wang H; Wei L; Zhao L; Li Z; Lu N; Guo Q
Toxicol Appl Pharmacol; 2013 Sep; 271(2):144-55. PubMed ID: 23707765
[TBL] [Abstract][Full Text] [Related]
15. Brusatol-Mediated Inhibition of c-Myc Increases HIF-1α Degradation and Causes Cell Death in Colorectal Cancer under Hypoxia.
Oh ET; Kim CW; Kim HG; Lee JS; Park HJ
Theranostics; 2017; 7(14):3415-3431. PubMed ID: 28912885
[TBL] [Abstract][Full Text] [Related]
16. Different antiproliferative effects of matuzumab and cetuximab in A431 cells are associated with persistent activity of the MAPK pathway.
Meira DD; Nóbrega I; de Almeida VH; Mororó JS; Cardoso AM; Silva RLA; Albano RM; Ferreira CG
Eur J Cancer; 2009 May; 45(7):1265-1273. PubMed ID: 19167213
[TBL] [Abstract][Full Text] [Related]
17. Effects of ras and von Hippel-Lindau (VHL) gene mutations on hypoxia-inducible factor (HIF)-1alpha, HIF-2alpha, and vascular endothelial growth factor expression and their regulation by the phosphatidylinositol 3'-kinase/Akt signaling pathway.
Blancher C; Moore JW; Robertson N; Harris AL
Cancer Res; 2001 Oct; 61(19):7349-55. PubMed ID: 11585776
[TBL] [Abstract][Full Text] [Related]
18. Epidermal growth factor receptor (EGFR) targeted therapies in non-small cell lung cancer (NSCLC).
Metro G; Finocchiaro G; Toschi L; Bartolini S; Magrini E; Cancellieri A; Trisolini R; Castaldini L; Tallini G; Crino L; Cappuzzo F
Rev Recent Clin Trials; 2006 Jan; 1(1):1-13. PubMed ID: 18393776
[TBL] [Abstract][Full Text] [Related]
19. PIK3CA mutation/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab.
Jhawer M; Goel S; Wilson AJ; Montagna C; Ling YH; Byun DS; Nasser S; Arango D; Shin J; Klampfer L; Augenlicht LH; Perez-Soler R; Mariadason JM
Cancer Res; 2008 Mar; 68(6):1953-61. PubMed ID: 18339877
[TBL] [Abstract][Full Text] [Related]
20. Epidermal growth factor receptor (EGFR) antibody down-regulates mutant receptors and inhibits tumors expressing EGFR mutations.
Perez-Torres M; Guix M; Gonzalez A; Arteaga CL
J Biol Chem; 2006 Dec; 281(52):40183-92. PubMed ID: 17082181
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
